This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo


Oral formulations of tafamidis.

Drugs List

  • tafamidis 61mg capsules
  • VYNDAQEL 61mg capsules
  • Therapeutic Indications


    Treatment of wild-type or hereditary ATTR-CM

    Treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy.


    Tafamidis and tafamidis meglumine are not interchangeable on a per mg basis.


    The recommended dose is 61mg of tafamidis once daily.

    Additional Dosage Information

    If vomiting occurs after dosing and the capsule is identified and intact, then an additional dose should be administered. If no capsule is identified, then no additional dose is necessary. Resume with next day dosing as usual.


    Children under 18 years
    Solid organ transplant recipients
    Hereditary fructose intolerance

    Precautions and Warnings

    Females of childbearing potential
    New York Heart Association class IV failure
    Renal impairment - creatinine clearance below or equal to 30ml/minute
    Severe hepatic impairment

    Treatment to be initiated and supervised by a specialist
    Presentations with sorbitol unsuitable in hereditary fructose intolerance
    May affect results of some laboratory tests
    Discontinue if patient undergoes organ transplant
    Female: Contraception required during and for 1 month after treatment

    Patients should be monitored continually to assess the need for other therapy, including the need for organ transplantation.

    Before treatment begins with 61mg dose, ensure patients presenting with specific medical history or signs of heart failure or cardiomyopathy have an aetiologic diagnosis to confirm transthyretin amyloidosis with cardiomyopathy and exclude AL amyloidosis. Diagnosis should be performed via bone scintigraphy and blood/urine assessment and/or by biopsy, and transthyretin genotyping to characterise as wild type or hereditary.

    Treatment should be initiated as soon as possible in the disease course. However if amyloid related cardiac damage is advanced such as New York Heart Association Class III, treatment initiation or continuation is taken at the discretion of the physician.

    Pregnancy and Lactation


    Tafamidis is contraindicated during pregnancy.

    The manufacturers do not recommend using tafamidis during pregnancy and in women of childbearing potential not using contraception. Animal studies have shown developmental toxicity. Human data is limited and as such a potential risk cannot be ruled out.


    Tafamidis is contraindicated during breastfeeding.

    The manufacturers do not recommend breastfeeding whilst taking tafamidis. Animal studies indicate tafamidis is expressed in the breast milk, but the quantity is unknown.

    Side Effects

    Altered liver function tests

    Effects on Laboratory Tests

    An increase in liver function tests and a decrease in total thyroxine with no accompanying change to free thyroxine (T4) or thyroid stimulating hormone (TSH) may occur during tafamidis treatment.


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: September 2020

    Reference Sources

    Summary of Product Characteristics: Vyndaqel 61mg soft capsules. Pfizer Ltd. Revised February 2020.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.